An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin
- Conditions
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 250
- Registration Number
- NCT00274443
- Locations
- 🇷🇺
Study Sites in Russia, St. Petersburg, Saint Petersburg, Russian Federation
Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 302
- Registration Number
- NCT00274456
- Locations
- 🇺🇦
Study Sites in Russia and the Ukraine, Kiev, Ukraine
Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 9
- Registration Number
- NCT00249002
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-11-28
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 43
- Registration Number
- NCT00179673
- Locations
- 🇺🇸
Alta Bates Cancer Center, Berkeley, California, United States
🇺🇸Pacific Coast Hematology/Oncology Medical Group, Onc., Fountain Valley, California, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2006-12-20
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00179686
- Locations
- 🇺🇸
Cancer and Blood Institute, Metairie, Louisiana, United States
🇺🇸Rush Cancer Institute, Chicago, Illinois, United States
🇺🇸Birmingham Cancer Center, Birmingham, Alabama, United States
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2006-04-12
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT00179725
- Locations
- 🇺🇸
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸OU Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸University of California at San Francisco, San Francisco, California, United States
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-11-23
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00179738
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Alta Bates Cancer Center, Berkeley, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-11-07
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00179699
- Locations
- 🇺🇸
MD Anderson - Orlando, Orlando, Florida, United States
🇺🇸Washington University, St. Louis, Missouri, United States
🇺🇸North Shore Hem/Onc Associates, East Setauket, New York, United States
A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-11-07
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT00179751
- Locations
- 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸Cancer and Blood Institute, Metairie, Louisiana, United States
🇺🇸Charleston Cancer Center, Charleston, South Carolina, United States
Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT00179660
- Locations
- 🇺🇸
UC David Cancer Center, Sacramento, California, United States
🇺🇸New York Medical Center, MBCCOP, Bronx, New York, United States
🇺🇸Sylvester Cancer CenterUniversity Of Miami, Miami, Florida, United States